| 英文名稱 |
中文名稱 |
CAS號 |
操作 |
| Vonoprazan |
沃諾拉贊 |
881681-00-1 |
詳細
|
| ApreMilast |
阿普斯特 |
608141-41-9 |
詳細
|
| 1-Methylcyclopropanecarboxylic acid |
1-甲基環(huán)丙烷-1-羧酸 |
6914-76-7 |
詳細
|
| (R)-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol |
(R)-(-)-甘油醇縮丙酮 |
14347-78-5 |
詳細
|
| Ibrutinib (PCI-32765) |
依魯替尼 |
936563-96-1 |
詳細
|
| Crisaborole |
克立硼羅 |
906673-24-3 |
詳細
|
| Ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate |
2-(3-醛基-4-異丁氧基苯基)-4-甲基噻唑-5-甲酸乙酯 |
161798-03-4 |
詳細
|
| Febuxostat |
非布司他 |
144060-53-7 |
詳細
|
| Ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate |
2-(4-羥基苯基)-4-甲基噻唑-5-羧酸乙酯 |
161797-99-5 |
詳細
|
| 4-hydroxythiobenzamide |
4-羥基硫代苯甲酰胺 |
25984-63-8 |
詳細
|
| Ethyl 2-(3-formyl-4- hydroxyphenyl)-4-
methylthiazole-5-carboxylate |
2-(3-醛基-4-羥基苯基)-4-甲基噻唑-5-羧酸乙酯 |
161798-01-2 |
詳細
|
| Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate |
2-(3-氰基-4-羥基苯基)-4-甲基-1,3-噻唑-5-羧酸乙酯 |
161798-02-3 |
詳細
|
| Entecavir hydrate |
恩替卡韋一水合物 |
209216-23-9 |
詳細
|
| (4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one |
(4S)-3-[(5S)-5-(4-氟苯基)-5-羥基戊酰基]-4-苯基-1,3-氧氮雜環(huán)戊烷-2-酮 |
189028-95-3 |
詳細
|
| Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate |
2-(3-氰基-4-異丁氧基苯基)-4-甲基-5-噻唑甲酸乙酯 |
160844-75-7 |
詳細
|
| (S)-1-(4-Fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione |
(4S)-3-[5-(4-氟苯基)-1,5-二氧代戊基]-4-苯基-2-惡唑烷酮 |
189028-93-1 |
詳細
|
| Ezetimibe |
依折麥布 |
163222-33-1 |
詳細
|
| Diisopropylamine dichloroacetate |
二氯醋酸二異丙胺 |
660-27-5 |
詳細
|
| Dacliximab |
達昔單抗 |
152923-56-3 |
詳細
|
| Siltuximab |
SILTUXIMAB ( 塞妥昔單抗 ) |
541502-14-1 |
詳細
|
| Apalutamide |
阿帕魯胺 |
956104-40-8 |
詳細
|
| Abemaciclib |
阿貝西利 |
1231929-97-7 |
詳細
|
| Bevacizumab |
貝伐珠單抗 |
216974-75-3 |
詳細
|
| Matuzumab |
馬妥珠單抗 |
339186-68-4 |
詳細
|
| Narsoplimab |
NARSOPLIMAB (納索利單抗 ) |
2108782-45-0 |
詳細
|
| Lorvotuzumab Mertansine |
Lorvotuzumab Mertansine |
1008106-64-6 |
詳細
|
| Alemtuzumab |
阿倫單抗 |
216503-57-0 |
詳細
|
| Sarilumab |
SARILUMAB |
1189541-98-7 |
詳細
|
| Research Grade Fontolizumab |
Immunoglobulin G1, anti-(human interferon g) (human-mouse monoclonal HuZAF g1-chain), disulfide with human-mouse monoclonal HuZAF light chain, dimer |
326859-36-3 |
詳細
|
| dupilumab |
度匹魯單抗 |
1190264-60-8 |
詳細
|
| Labetuzumab |
Immunoglobulin G,anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 g-chain), disulfide withhuman-mouse monoclonal hMN-14 k-chain, dimer |
219649-07-7 |
詳細
|
| Ixekizumab |
伊西貝單抗 |
1143503-69-8 |
詳細
|
| Nivolumab |
納武單抗 |
946414-94-4 |
詳細
|
| Ruplizumab |
RUPLIZUMAB |
220651-94-5 |
詳細
|
| Gemtuzumab |
吉妥珠單抗奧唑米星 |
220578-59-6 |
詳細
|
| EFALIZUMABUM |
EFALIZUMABUM |
214745-43-4 |
詳細
|
| Lambrolizumab |
派姆單抗 |
1374853-91-4 |
詳細
|
| Lintuzumab |
Lintuzumab |
166089-32-3 |
詳細
|
| TocilizuMab |
托珠單抗 |
375823-41-9 |
詳細
|
| Lymphocide |
Lymphocide |
205923-57-5 |
詳細
|
| Eculizumab |
托西珠單抗 |
219685-50-4 |
詳細
|
| Hu1D10 |
Hu1D10 |
267227-08-7 |
詳細
|
| cantuzumab mertansine |
cantuzumab mertansine |
400010-39-1 |
詳細
|
| Topiroxostat |
托匹司他 |
577778-58-6 |
詳細
|
| Neratinib |
來那替尼 |
688387-09-6 |
詳細
|
| Carbazochrome Sodium Sulfonate |
卡絡磺鈉 |
51460-26-5 |
詳細
|
| NEW PRODUCTS INTRODUCTION |
|
|
詳細
|
| Pomalidomide |
泊馬度胺 |
19171-19-8 |
詳細
|
| 4,4-dimethyl-3,5,8-
trioxabicyclo[5.1.0]octane |
4,4-二甲基-3,5,8-三氧雜雙環(huán)[5,1,0]辛烷 |
57280-22-5 |
詳細
|
| Erlotinib Hydrochloride |
埃羅替尼 |
183321-74-6 |
詳細
|
| Olaparib |
奧拉帕尼 |
763113-22-0 |
詳細
|
| Rafivirumab |
瑞非韋魯 |
944548-37-2 |
詳細
|
| Arcitumomab |
阿西莫單抗 |
154361-48-5 |
詳細
|
| Imciromab |
英西單抗 |
126132-83-0 |
詳細
|
| Satumomab |
沙妥莫單抗 |
144058-40-2 |
詳細
|
| Biciromab |
Biciromab |
138783-13-8 |
詳細
|
| Gevokizumab |
吉伏組單抗 |
1129435-60-4 |
詳細
|
| Ranibizumab |
雷尼株單抗 |
347396-82-1 |
詳細
|
| Edobacomab |
埃巴單抗 |
141410-98-2 |
詳細
|
| Odulimomab |
奧度莫單抗 |
159445-64-4 |
詳細
|
| Inolimomab |
伊諾莫單抗 |
152981-31-2 |
詳細
|
| Pascolizumab |
Sb-240683 |
331243-22-2 |
詳細
|
| Abagovomab |
ABAGOVOMAB |
792921-10-9 |
詳細
|
| Enlimomab |
恩莫單抗 |
142864-19-5 |
詳細
|
| Oregovomab |
OregovoMab |
213327-37-8 |
詳細
|
| Research Grade T10B9.1A-31 |
|
|
詳細
|
| Research Grade Tecnemab |
|
|
詳細
|
| Iodine (131I) Derlotuximab Biotin |
Cotara (9CI) |
340013-96-9 |
詳細
|
| Abciximab |
ABCIXIMAB |
143653-53-6 |
詳細
|
| Bavituximab |
巴維昔單抗 |
648904-28-3 |
詳細
|
| Basiliximab |
巴利昔單抗 |
179045-86-4 |
詳細
|
| Research Grade cT84.66 |
|
|
詳細
|
| Tositumomab |
bexxar |
208921-02-2 |
詳細
|
| Research Grade Immurait-Ll2Mab |
|
|
詳細
|
| Nofetumomab |
Merpentan |
165942-79-0 |
詳細
|
| Sulesomab |
硫索單抗 |
167747-19-5 |
詳細
|
| Capromab |
CAPROMAB |
145464-28-4 |
詳細
|
| Sevirumab |
司韋單抗 |
|
詳細
|
| Visilizumab |
VISILIZUMAB |
219716-33-3 |
詳細
|
| Igovomab |
伊戈伏單抗 |
171656-50-1 |
詳細
|
| Mitumomab |
Mitumomab |
216503-58-1 |
詳細
|
| Research Grade Cc49 |
|
|
詳細
|
| Gavilimomab |
Immunoglobulin M,anti-(human CD147 (antigen)) (mouse monoclonal ABX-CBL m-chain), disulfide with mousemonoclonal ABX-CBL light chain, pentamer |
244096-20-6 |
詳細
|
| Foravirumab |
夫瑞韋如 |
944548-38-3 |
詳細
|
| Research Grade Afelimomab |
阿非莫單抗 |
156227-98-4 |
詳細
|
| Milatuzumab |
米拉組單抗 |
899796-83-9 |
詳細
|
| Edrecolomab |
依決洛單抗 |
156586-89-9 |
詳細
|
| mepolizumab |
美泊利單抗 |
196078-29-2 |
詳細
|
| Tadocizumab |
tadocizumab |
339086-80-5 |
詳細
|
| Pexelizumab |
h5G1.1-scFv |
219685-93-5 |
詳細
|
| Natalizumab |
那他珠單抗 |
189261-10-7 |
詳細
|
| Omalizumab |
奧馬珠單抗 |
242138-07-4 |
詳細
|
| Amatuximab |
阿麥妥單抗 |
931402-35-6 |
詳細
|
| Siplizumab |
SIPLIZUMAB ( 西利珠單抗 ) |
288392-69-8 |
詳細
|
| palivizumab |
帕利珠單抗 |
188039-54-5 |
詳細
|
| nimotuzumab |
nimotuzumab |
828933-51-3 |
詳細
|
| Pertuzumab |
帕妥珠單抗 |
380610-27-5 |
詳細
|
| Motavizumab |
莫維珠單抗 |
677010-34-3 |
詳細
|
| Naptumomab Estafenatox |
埃托-那普妥莫單抗 |
676258-98-3 |
詳細
|
| Research Grade Cedelizumab |
Immunoglobulin G4,anti-(human CD4 (antigen)) (human-mouse monoclonal OKTcdr4a complementarydetermining region-grafted g4-chain), disulfide with human-mouse monoclonal OKTcdr4a complementarydetermining region-grafted k-chain, dimer (9CI) |
156586-90-2 |
詳細
|